NCT02579772View on ClinicalTrials.gov

Effects of N-acetylcysteine on Cardiorespiratory Control in COPD Patients With Mild-to-moderate Airflow Obstruction

PHASE4CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

N-acetylcysteine

Pharmacological treatment with N-acetylcysteine (NAC): 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment.

DRUG

Placebo

Placebo: 3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.

All Listed Sponsors
lead

Queen's University

OTHER

NCT02579772 - Effects of N-acetylcysteine on Cardiorespiratory Control in COPD Patients With Mild-to-moderate Airflow Obstruction | Biotech Hunter | Biotech Hunter